Literature DB >> 16818170

Clinical manifestations and management of neurofibromatosis type 1.

James H Tonsgard1.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with variable expression. The complications are age specific. Neurologic complications include tumors of the peripheral nerves, nerve roots, and plexi; spinal cord compression; dural ectasias; learning disabilities; attention deficit; headaches; seizures; brain tumors; deafness; hydrocephalus; and stroke. High-intensity signals on brain magnetic resonance imaging are a frequent finding without known clinical significance. Most brain tumors are benign and asymptomatic, but malignant brain tumors occur. The major cause of death is malignancy, including brain tumors and malignant peripheral nerve sheath tumors. Management includes genetic counseling, regular eye examinations, and careful physical exams.

Entities:  

Mesh:

Year:  2006        PMID: 16818170     DOI: 10.1016/j.spen.2006.01.005

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  62 in total

Review 1.  A large intrathoracic meningocele in a patient with neurofibromatosis-1.

Authors:  Jae Wook Jeong; Kwang Young Park; Sang Min Yoon; Du Whan Choe; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  Korean J Intern Med       Date:  2010-06-01       Impact factor: 2.884

2.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

3.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Wei Mo; Jian Chen; Amish Patel; Liang Zhang; Vincent Chau; Yanjiao Li; Woosung Cho; Kyun Lim; Jing Xu; Alexander J Lazar; Chad J Creighton; Svetlana Bolshakov; Renée M McKay; Dina Lev; Lu Q Le; Luis F Parada
Journal:  Cell       Date:  2013-02-21       Impact factor: 41.582

4.  Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.

Authors:  Galina Semenova; Dina S Stepanova; Sergey M Deyev; Jonathan Chernoff
Journal:  Biochimie       Date:  2017-01-06       Impact factor: 4.079

5.  PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity.

Authors:  Kavitha Nutakki; James W Varni; Nancy L Swigonski
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

6.  Nf1 expression is dependent on strain background: implications for tumor suppressor haploinsufficiency studies.

Authors:  Jessica J Hawes; Robert G Tuskan; Karlyne M Reilly
Journal:  Neurogenetics       Date:  2007-01-11       Impact factor: 2.660

7.  Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1.

Authors:  Alanna M Kongkriangkai; Christopher King; Lisa J Martin; Emily Wakefield; Carlos E Prada; Geraldine Kelly-Mancuso; Elizabeth K Schorry
Journal:  Am J Med Genet A       Date:  2019-02-08       Impact factor: 2.802

8.  Distribution and Within-Family Specificity of Quantitative Autistic Traits in Patients with Neurofibromatosis Type I.

Authors:  John N Constantino; Yi Zhang; Kieran Holzhauer; Sayli Sant; Kyna Long; Alicia Vallorani; Leena Malik; David H Gutmann
Journal:  J Pediatr       Date:  2015-06-04       Impact factor: 4.406

9.  Attitudes about internet support groups among adolescents and young adults with neurofibromatosis type 1 and their parents.

Authors:  Staci Martin; Pamela L Wolters; Andrea Baldwin; Marie Claire Roderick; Mary Anne Toledo-Tamula; Andrea Gillespie; Brigitte Widemann
Journal:  J Genet Couns       Date:  2014-01-28       Impact factor: 2.537

Review 10.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.